Protocol Ledger

NCT05014438 · Phase II · COMPLETED

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

Interventional Phase II clinical trial protocol NCT05014438 sponsored by Bristol Myers Squibb in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-17 Enrollment: 17 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05014438
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)17 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05014438
Protocol FieldVerified Registry Value
NCT IdentifierNCT05014438
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment17 participants (ACTUAL)
Registered Start Date2021-08-17
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI